Santhera Pharmaceuticals secures CHF 45 million in funding. The advisors

Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on the development and commercialisation of innovative medicines for rare neuromuscular
neuromuscular and pulmonary diseases with high unmet medical need, has announced an equity financing of CHF 20 million via a private placement of shares, a placement of private convertible bonds of CHF 15 million and upsizing of an existing financing arrangement of up to CHF 10 million. In addition, Santhera agreed to issue warrants to participating investors. 

H.C. Wainwright & Co. is acting as exclusive placement agent for the private placement, consisting of shares and purchase warrants. The aggregate gross proceeds from the private placement amount to approximately CHF 20 million and potential gross proceeds from the purchase warrants amount to CHF 12.5 million. 

The advisors

Homburger advised Santhera in this matter. The team was led by partners Dieter Gericke and Daniel Häusermann (both capital markets, pictured top). Key members of the team included partner Stefan Oesterhelt (tax), counsel Eduard De Zordi (capital markets), associates Margrit Marti, Francesco Bernasconi and Romain Fakhoury (all capital markets), as well as junior associate Natalie Pompe. 

Pestalozzi advised H.C. Wainwright & Co. in relation to all matters of Swiss law and rules of the SIX Swiss Exchange. The Pestalozzi team included Christian Leuenberger  (lead partner, capital markets / m&a, pictured left), Severin Roelli (partner, corporate / m&a), Monika Maric (associate, capital markets / m&a)